VENCLEXTA (venetoclax) in AML: An Australian Perspective
~6 mins
In this video, Professor Steven Lane from the Royal Brisbane and Women’s Hospital and QIMR Berghofer Medical Research Institute, shares his perspective on VENCLEXTA as a treatment for newly-diagnosed patients with acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. He reviews the key information from the VIALE-A clinical trial of VENCLEXTA and azacitidine combination and provides some guidance on treating AML patients with VENCLEXTA.
YOU MIGHT ALSO BE INTERESTED IN...
VENCLEXTA in AML:
Management & mitigation strategies
~5 mins
AML management:
An introduction to VENCLEXTA
~3 mins
VENCLEXTA in AML:
Phase III studies
~6 mins
Contact
Discover more about how we can help you in your practice.
PBS Information
Venclexta: VENCLEXTA (venetoclax) in combination with rituximab is PBS listed for relapsed or refractory chronic lymphocytic leukaemia (CLL). VENCLEXTA in combination with obinutuzumab is PBS listed for first line treatment of CLL or small lymphocytic lymphoma (SLL). VENCLEXTA in combination with azacitidine is PBS listed for treatment of acute myeloid leukaemia (AML). General Schedule listing. Authority required (telephone). Refer to PBS schedule for full authority information. VENCLEXTA monotherapy is not listed on the PBS. VENCLEXTA in combination with low-dose cytarabine is not listed on the PBS for treatment of AML.
Please review the full Product Information (PI) before prescribing, available below.
AML: acute myeloid leukaemia.
AU-VENA-220031 September 2022